Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder

For The Autism And Developmental Disorders Inpatient Research Collaborative (Addirc)

doi:10.1007/s10803-017-3153-x

Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder

For The Autism And Developmental Disorders Inpatient Research Collaborative (Addirc)

Communication Sciences and Disorders

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.

Original language	English (US)
Pages (from-to)	3711-3719
Number of pages	9
Journal	Journal of Autism and Developmental Disorders
Volume	48
Issue number	11
DOIs	https://doi.org/10.1007/s10803-017-3153-x
State	Published - Nov 1 2018

All Science Journal Classification (ASJC) codes

Developmental and Educational Psychology

Access to Document

10.1007/s10803-017-3153-x

Cite this

@article{4f8dbc96829b4e15b992420af1c5569c,

title = "Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder",

abstract = "Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.",

author = "{For The Autism And Developmental Disorders Inpatient Research Collaborative (Addirc)} and Wink, {Logan K.} and Pedapati, {Ernest V.} and Ryan Adams and Erickson, {Craig A.} and Pedersen, {Kahsi A.} and Morrow, {Eric M.} and Desmond Kaplan and Matthew Siegel and Matthew Siegel and Craig Erickson and Gabriels, {Robin L.} and Desmond Kaplan and Carla Mazefsky and Morrow, {Eric M.} and Giulia Righi and Santangelo, {Susan L.} and Logan Wink and Jill Benevides and Carol Beresford and Carrie Best and Katie Bowen and Briar Dechant and Tom Flis and Holly Gastgeb and Angela Geer and Louis Hagopian and Benjamin Handen and Adam Klever and Martin Lubetsky and Kristen MacKenzie and Zenoa Meservy and John McGonigle and Kelly McGuire and Faith McNeil and Joshua Montrenes and Tamara Palka and Ernest Pedapati and Pedersen, {Kahsi A.} and Christine Peura and Joseph Pierri and Christie Rogers and Brad Rossman and Jennifer Ruberg and Elise Sannar and Cathleen Small and Nicole Stuckey and Barbara Tylenda and Mary Verdi and Jessica Vezzoli and Diane Williams",

note = "Funding Information: The ADDIRC is made up of these co-investigators: Matthew Siegel, MD (PI) (Maine Medical Center Research Institute; Tufts University), Craig Erickson, MD (Cincinnati Children?s Hospital; University of Cincinnati), Robin L. Gabriels, PsyD (Children?s Hospital Colorado; University of Colorado), Desmond Kaplan, MD (Sheppard Pratt Health System), Carla Mazefsky, PhD (Western Psychiatric Institute and Clinics; University of Pittsburgh), Eric M. Morrow, MD, PhD (Bradley Hospital; Brown University), Giulia Righi, PhD (Bradley Hospital; Brown University), Susan L Santangelo, ScD (Maine Medical Center Research Institute; Tufts University), and Logan Wink, MD (Cincinnati Children?s Hospital; University of Cincinnati). Collaborating investigators and staff: Jill Benevides, BS, Carol Beresford, MD, Carrie Best, MPH, Katie Bowen, LCSW, Briar Dechant, BS, Tom Flis, BCBA, LCPC, Holly Gastgeb, PhD, Angela Geer, BS, Louis Hagopian, PhD, Benjamin Handen, PhD, BCBA-D, Adam Klever, BS, Martin Lubetsky, MD, Kristen MacKenzie, BS, Zenoa Meservy, MD, John McGonigle, PhD, Kelly McGuire, MD, Faith McNeil, BS, Joshua Montrenes, BS, Tamara Palka, MD, Ernest Pedapati, MD, Kahsi A. Pedersen, PhD, Christine Peura, BA, Joseph Pierri, MD, Christie Rogers, MS, CCC-SLP, Brad Rossman, MA, Jennifer Ruberg, LISW, Elise Sannar, MD, Cathleen Small, PhD Nicole Stuckey, MSN, RN, Barbara Tylenda, PhD, Mary Verdi, MA, Jessica Vezzoli, BS, Deanna Williams, BA, and Diane Williams, PhD, CCC-SLP. We gratefully acknowledge the contributions of the coordinating site advisory group: Donald L. St. Germain, MD and Girard Robinson, MD, and our scientific advisory group: Connie Kasari, PhD., Bryan King, MD, James McCracken, MD, Christopher McDougle, MD, Lawrence Scahill, MSN, PhD, Robert Schultz, PhD and Helen Tager-Flusberg, PhD, the input of the funding organizations and the families and children who participated. LW participated in acquisition of the data, drafting and revision of the manuscript, and approval of the final draft. EP, CE, EM, and DK participated in acquisition of the data, revision of the manuscript, and approval of the final draft. RA and KP completed statistical analysis of the data, participated in drafting and revision of the manuscript, and approved the final draft. MS participated in conception and design of the study, revision of the manuscript, and approval of the final draft. The Autism Inpatient Collection (AIC) phenotypic database and biorepository is supported by a grant from the Simons Foundation Autism Research Initiative and the Nancy Lurie Marks Family Foundation, (SFARI #296318 to M.S.). The members of ADDIRC are listed in Acknowledgments section. The authors report no direct conflicts of interest with this report. Dr. Wink?s current research is supported by the Simons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Pedapati receives research support from the Cincinnati Children?s Hospital Research Foundation. Dr. Erickson is a consultant to and holds equity in Confluence Pharmaceuticals and is a consultant to Neurotrope and Fulcrum. Dr. Erickson is a past consultant to Alcobra Pharmaceuticals, the Roche Group, and Novartis. Dr. Erickson holds non-related IP held by CCHMC and Indiana University. Dr. Erickson receives or has received research grant support from the John Merck Fund, Indiana University School of Medicine, Cincinnati Children?s Hospital Medical Center, Autism Speaks, the United States Department of Defense, the Simons Foundation, the United States Centers for Disease Control, the National Fragile X Foundation, The Roche Group, Neuren Pharmaceuticals, the National Institutes of Health, and Riovant Sciences Ltd. Dr. Morrow is supported by the National Institute of Mental Health (R01 MH105442) and a grant from the Simons Foundation Autism Research Initiative (SFARI #286756 to EMM). Dr. Kaplan and Dr. Siegel report no conflicts of interest. Funding Information: Funding The Autism Inpatient Collection (AIC) phenotypic database and biorepository is supported by a grant from the Simons Foundation Autism Research Initiative and the Nancy Lurie Marks Family Foundation, (SFARI #296318 to M.S.). Funding Information: Conflict of interest The authors report no direct conflicts of interest with this report. Dr. Wink{\textquoteright}s current research is supported by the Si-mons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Pedapati receives research support from the Cincinnati Children{\textquoteright}s Hospital Research Foundation. Dr. Erickson is a consultant to and holds equity in Confluence Pharmaceuticals and is a consultant to Neurotrope and Fulcrum. Dr. Erickson is a past consultant to Alcobra Pharmaceuticals, the Roche Group, and Novartis. Dr. Erickson holds non-related IP held by CCHMC and Indiana University. Dr. Erickson receives or has received research grant support from the John Merck Fund, Indiana University School of Medicine, Cincinnati Children{\textquoteright}s Hospital Medical Center, Autism Speaks, the United States Department of Defense, the Simons Foundation, the United States Centers for Disease Control, the National Fragile X Foundation, The Roche Group, Neuren Pharmaceuticals, the National Institutes of Health, and Riovant Sciences Ltd. Dr. Morrow is supported by the National Institute of Mental Health (R01 MH105442) and a grant from the Simons Foundation Autism Research Initiative (SFARI #286756 to EMM). Dr. Kaplan and Dr. Siegel report no conflicts of interest. Publisher Copyright: {\textcopyright} 2017, Springer Science+Business Media New York.",

year = "2018",

month = nov,

day = "1",

doi = "10.1007/s10803-017-3153-x",

language = "English (US)",

volume = "48",

pages = "3711--3719",

journal = "Journal of Autism and Developmental Disorders",

issn = "0162-3257",

publisher = "Springer New York",

number = "11",

}

TY - JOUR

T1 - Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder

AU - For The Autism And Developmental Disorders Inpatient Research Collaborative (Addirc)

AU - Wink, Logan K.

AU - Pedapati, Ernest V.

AU - Adams, Ryan

AU - Erickson, Craig A.

AU - Pedersen, Kahsi A.

AU - Morrow, Eric M.

AU - Kaplan, Desmond

AU - Siegel, Matthew

AU - Erickson, Craig

AU - Gabriels, Robin L.

AU - Kaplan, Desmond

AU - Mazefsky, Carla

AU - Morrow, Eric M.

AU - Righi, Giulia

AU - Santangelo, Susan L.

AU - Wink, Logan

AU - Benevides, Jill

AU - Beresford, Carol

AU - Best, Carrie

AU - Bowen, Katie

AU - Dechant, Briar

AU - Flis, Tom

AU - Gastgeb, Holly

AU - Geer, Angela

AU - Hagopian, Louis

AU - Handen, Benjamin

AU - Klever, Adam

AU - Lubetsky, Martin

AU - MacKenzie, Kristen

AU - Meservy, Zenoa

AU - McGonigle, John

AU - McGuire, Kelly

AU - McNeil, Faith

AU - Montrenes, Joshua

AU - Palka, Tamara

AU - Pedapati, Ernest

AU - Pedersen, Kahsi A.

AU - Peura, Christine

AU - Pierri, Joseph

AU - Rogers, Christie

AU - Rossman, Brad

AU - Ruberg, Jennifer

AU - Sannar, Elise

AU - Small, Cathleen

AU - Stuckey, Nicole

AU - Tylenda, Barbara

AU - Verdi, Mary

AU - Vezzoli, Jessica

AU - Williams, Diane

N1 - Funding Information: The ADDIRC is made up of these co-investigators: Matthew Siegel, MD (PI) (Maine Medical Center Research Institute; Tufts University), Craig Erickson, MD (Cincinnati Children?s Hospital; University of Cincinnati), Robin L. Gabriels, PsyD (Children?s Hospital Colorado; University of Colorado), Desmond Kaplan, MD (Sheppard Pratt Health System), Carla Mazefsky, PhD (Western Psychiatric Institute and Clinics; University of Pittsburgh), Eric M. Morrow, MD, PhD (Bradley Hospital; Brown University), Giulia Righi, PhD (Bradley Hospital; Brown University), Susan L Santangelo, ScD (Maine Medical Center Research Institute; Tufts University), and Logan Wink, MD (Cincinnati Children?s Hospital; University of Cincinnati). Collaborating investigators and staff: Jill Benevides, BS, Carol Beresford, MD, Carrie Best, MPH, Katie Bowen, LCSW, Briar Dechant, BS, Tom Flis, BCBA, LCPC, Holly Gastgeb, PhD, Angela Geer, BS, Louis Hagopian, PhD, Benjamin Handen, PhD, BCBA-D, Adam Klever, BS, Martin Lubetsky, MD, Kristen MacKenzie, BS, Zenoa Meservy, MD, John McGonigle, PhD, Kelly McGuire, MD, Faith McNeil, BS, Joshua Montrenes, BS, Tamara Palka, MD, Ernest Pedapati, MD, Kahsi A. Pedersen, PhD, Christine Peura, BA, Joseph Pierri, MD, Christie Rogers, MS, CCC-SLP, Brad Rossman, MA, Jennifer Ruberg, LISW, Elise Sannar, MD, Cathleen Small, PhD Nicole Stuckey, MSN, RN, Barbara Tylenda, PhD, Mary Verdi, MA, Jessica Vezzoli, BS, Deanna Williams, BA, and Diane Williams, PhD, CCC-SLP. We gratefully acknowledge the contributions of the coordinating site advisory group: Donald L. St. Germain, MD and Girard Robinson, MD, and our scientific advisory group: Connie Kasari, PhD., Bryan King, MD, James McCracken, MD, Christopher McDougle, MD, Lawrence Scahill, MSN, PhD, Robert Schultz, PhD and Helen Tager-Flusberg, PhD, the input of the funding organizations and the families and children who participated. LW participated in acquisition of the data, drafting and revision of the manuscript, and approval of the final draft. EP, CE, EM, and DK participated in acquisition of the data, revision of the manuscript, and approval of the final draft. RA and KP completed statistical analysis of the data, participated in drafting and revision of the manuscript, and approved the final draft. MS participated in conception and design of the study, revision of the manuscript, and approval of the final draft. The Autism Inpatient Collection (AIC) phenotypic database and biorepository is supported by a grant from the Simons Foundation Autism Research Initiative and the Nancy Lurie Marks Family Foundation, (SFARI #296318 to M.S.). The members of ADDIRC are listed in Acknowledgments section. The authors report no direct conflicts of interest with this report. Dr. Wink?s current research is supported by the Simons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Pedapati receives research support from the Cincinnati Children?s Hospital Research Foundation. Dr. Erickson is a consultant to and holds equity in Confluence Pharmaceuticals and is a consultant to Neurotrope and Fulcrum. Dr. Erickson is a past consultant to Alcobra Pharmaceuticals, the Roche Group, and Novartis. Dr. Erickson holds non-related IP held by CCHMC and Indiana University. Dr. Erickson receives or has received research grant support from the John Merck Fund, Indiana University School of Medicine, Cincinnati Children?s Hospital Medical Center, Autism Speaks, the United States Department of Defense, the Simons Foundation, the United States Centers for Disease Control, the National Fragile X Foundation, The Roche Group, Neuren Pharmaceuticals, the National Institutes of Health, and Riovant Sciences Ltd. Dr. Morrow is supported by the National Institute of Mental Health (R01 MH105442) and a grant from the Simons Foundation Autism Research Initiative (SFARI #286756 to EMM). Dr. Kaplan and Dr. Siegel report no conflicts of interest. Funding Information: Funding The Autism Inpatient Collection (AIC) phenotypic database and biorepository is supported by a grant from the Simons Foundation Autism Research Initiative and the Nancy Lurie Marks Family Foundation, (SFARI #296318 to M.S.). Funding Information: Conflict of interest The authors report no direct conflicts of interest with this report. Dr. Wink’s current research is supported by the Si-mons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Pedapati receives research support from the Cincinnati Children’s Hospital Research Foundation. Dr. Erickson is a consultant to and holds equity in Confluence Pharmaceuticals and is a consultant to Neurotrope and Fulcrum. Dr. Erickson is a past consultant to Alcobra Pharmaceuticals, the Roche Group, and Novartis. Dr. Erickson holds non-related IP held by CCHMC and Indiana University. Dr. Erickson receives or has received research grant support from the John Merck Fund, Indiana University School of Medicine, Cincinnati Children’s Hospital Medical Center, Autism Speaks, the United States Department of Defense, the Simons Foundation, the United States Centers for Disease Control, the National Fragile X Foundation, The Roche Group, Neuren Pharmaceuticals, the National Institutes of Health, and Riovant Sciences Ltd. Dr. Morrow is supported by the National Institute of Mental Health (R01 MH105442) and a grant from the Simons Foundation Autism Research Initiative (SFARI #286756 to EMM). Dr. Kaplan and Dr. Siegel report no conflicts of interest. Publisher Copyright: © 2017, Springer Science+Business Media New York.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.

AB - Nearly 11% of youth with Autism Spectrum Disorder (ASD) undergo psychiatric hospitalization, and 65% are treated with psychotropic medication. Here we characterize psychotropic medication usage in subjects enrolled in the Autism Inpatient Collection. Participant psychotropic medication usage rates topped 90% at admission and discharge, though there was a decline at 2-month follow-up. Antipsychotics, ADHD medications, and sleep aids were the most commonly reported classes of medications. The impact of age, gender, and non-verbal IQ on medication usage rates was minimal, though age and IQ may play a role in prescribing practices. Future work is indicated to explore medication usage trends, the impact of clinical factors on medication use rates, and the safety of psychotropic medications in youth with ASD.

UR - http://www.scopus.com/inward/record.url?scp=85019543395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019543395&partnerID=8YFLogxK

U2 - 10.1007/s10803-017-3153-x

DO - 10.1007/s10803-017-3153-x

M3 - Article

C2 - 28516426

AN - SCOPUS:85019543395

VL - 48

SP - 3711

EP - 3719

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 11

ER -

Characterization of Medication Use in a Multicenter Sample of Pediatric Inpatients with Autism Spectrum Disorder

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this